文献速递临床试验与 GCP

比较两种剂量维生素D3在接受连续性肾脏替代治疗的危重患者中的应用(NephroD):一项单盲、多中心、平行组随机对照试验的研究方案

Comparison of two doses of vitamin D3 in critically ill patients undergoing continuous renal replacement therapy (NephroD): study protocol for a single-blinded, multicenter, parallel group randomized controlled trial.
PubMed 文献 · Trials · 2024-11-24

本研究为单盲、多中心、平行组随机对照试验方案,拟在波兰不超过五所大学医院纳入138例接受连续性肾脏替代治疗(CRRT)且血清25(OH)D3≤12.5 ng/ml的ICU患者,比较单次给予维生素D3 750,000 IU与500,000 IU的效果;主要结局为给药后第3天和第7天血清25(OH)D3≥30 ng/ml的患者百分比。

要点

  • ICU接受CRRT的严重维生素D3缺乏患者(25(OH)D3≤12.5 ng/ml)随机接受单次750,000 IU或500,000 IU维生素D3。
  • 主要结局为给药后第3天和第7天血清25(OH)D3≥30 ng/ml的患者百分比。
  • 假设脱落率约10%,计划招募138例患者。

核心结论

  • 该研究旨在帮助回答将补充剂量增加50%是否能确保接受CRRT的危重患者更有效地补充维生素D3的问题。

研究设计与样本

  • 单盲、多中心、平行组随机对照试验,在波兰不超过五所大学医院开展,比较单次经肠内或口服途径给予750,000 IU与500,000 IU维生素D3。
  • 研究对象为ICU中接受CRRT且血清25(OH)D3≤12.5 ng/ml的严重维生素D3缺乏患者。
  • 假设脱落率约10%,计划招募138例患者。

关键数值与推荐

  • 主要结局为给药后第3天和第7天血清25(OH)D3≥30 ng/ml的患者百分比。
  • 严重维生素D3缺乏定义为血清25(OH)D3≤12.5 ng/ml。
  • 干预剂量分别为单次750,000 IU和500,000 IU维生素D3,经肠内或口服途径给药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ICU patients are particularly susceptible to vitamin D3 deficiencies. This can be due to the severity of their underlying disease, the type of treatment they are on, and malnutrition before and inadequate nutrition during the hospitalization preceding ICU admission as well as advanced age. Literature provides no guidance on how to supplement vitamin D3 in severely deficient patients who are undergoing continuous renal replacement therapy (CRRT). Most serum 25(OH)D3 is bound with vitamin D binding protein in a complex whose molecular weight is 10 kDa. This means it can be removed during CRRT via convection mechanism. Critically ill patients undergoing CRRT can therefore be particularly prone to develop severe vitamin D3 deficiency. METHODS: As the trial design, a randomized controlled, single blinded, multicenter, parallel group approach was chosen to compare a single administration of 750,000 IU of vitamin D3 via the enteral or oral route in ICU patients with severe vitamin D3 deficiency (measured serum 25(OH)D3 levels ≤ 12.5 ng/ml) undergoing CRRT with a single administration of 500,000 IU of vitamin D3. The trial will be performed in up to five university hospitals in Poland. The primary outcome is the percentage of patients that achieved serum 25(OH)D3 levels ≥ 30 ng/ml on days 3 and 7 following vitamin D3 administration. Assuming a drop-out rate of approximately 10%, the number of recruited patients should be 138. DISCUSSION: Considering the potential pathophysiological mechanisms underlying hypovitaminosis D in critically ill patients under CRRT, it seems conceivable that these patients will require greater supplementation doses to correct severe deficiency. The study is meant to help answer the question whether increasing the supplementation dose by 50% will ensure a more effective replenishment of vitamin D3 in critically ill patients undergoing CRRT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05657678, registered: December 12 2022, https://clinicaltrials.gov/study/NCT05657678?cond=NCT05657678&rank=1 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Czarnik T, Bialka S, Borys M, et al. Comparison of two doses of vitamin D3 in critically ill patients undergoing continuous renal replacement therapy (NephroD): study protocol for a single-blinded, multicenter, parallel group randomized controlled trial. Trials. 2024. PMID: 39582029. doi:10.1186/s13063-024-08598-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。